PPARA and type 2 diabetes mellitus: Considering that chiglitazar has recently been approved in China to treat type 2 diabetes due to its moderate glucose-lowering effect, this medication may have specific advantage in treating MDD patients with type 2 diabetes in clinical practice in the future, compared to not only commonly used SSRIs and SNRIs but also other PPARα agonists such as fenofibrate and gemfibrozil.